
Publications

-
- 1 **Meijer E**, Hoekstra JBL. De keerzijde van scherpe diabetesregulatie. *Ned Tijdschr Geneesk* 1992; 35: 1689-1691.
 - 2 **Meijer E**, Hoekstra JBL, Erkelens DW. Hypoglycemia Unawareness. *Eur J Med* 1994; 23: 623-627.
 - 3 **Meijer E**, Hoekstra JBL. Severe hypoglycaemia during intensive insulin therapy: a reversibel phenomenon? Editorial. *Neth J Med* 1995; 46: 167-170.
 - 4 **Meijer E**, Westerveld HE, de Ruyter FC, van Greevenbroek MMJ, Rienks R, van Rijn HJM, Erkelens DW, de Bruin TWA. Abnormal postprandial apolipoprotein B48 and triglyceride responses in normolipidemic women with greater than 70 per cent stenotic coronary artery disease: a case-control study. *Atherosclerosis* 1996; 124: 221-235.
 - 5 Westerveld HE, **Meijer E**, Erkelens DW, de Bruin TWA. Postprandial reduction in high-density lipoprotein cholesterol concentrations in postmenopausal women: improvement by 17 β -estradiol. *Metabolism* 1996; 45: 827-832.
 - 6 Westerveld HE, **Meijer E**, de Bruin TWA, Erkelens DW. Estrogens and postprandial lipid metabolism. *Biochem Soc Trans* 1997; 25: 45-49.
 - 7 Cabezas MC, de Bruin TWA, Westerveld HE, **Meijer E**, Erkelens DW. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolemia. *J Int Med* 1998; 244: 299-307.
 - 8 van Esser JWJ, Niesters HGM, Thijsen SFT, **Meijer E**, Osterhaus ADME, Wolthers KC, Boucher ChAB, Gratama JW, Budel LM, van der Holt B, van Loon AM, Lowenberg B, Verdonck LF, Cornelissen JJ. Molecular quantitation of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus associated lymphoproliferative disease after allogeneic stem cell transplantation. *Br J Haematol* 2001; 113: 814-821.
 9. van Esser JWJ, van der Holt B, **Meijer E**, Niesters HGM, Trenschele R, Thijsen SFT, van Loon AM, Frassonni F, Bacigalupo A, Schaefer UW, Osterhaus ADME, Gratama JW, Lowenberg B, Verdonck LF, Cornelissen JJ. Epstein-Barr virus reactivation is a very frequent event after allogeneic stem cell transplantation and quantitatively predicts for EBV-lymphoproliferative disease following T-cell depleted stem cell transplantation. *Blood* 2001; 98: 972-978.
 - 10 van Esser JWJ, Niesters HGM, van der Holt B, **Meijer E**, Osterhaus ADME, Gratama JW, van Loon AM, Verdonck LF, Lowenberg B, Cornelissen JJ. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogeneic stem cell transplantation. *Blood* 2002; 99: 4364-4369.
 - 11 **Meijer E**, Slaper-Cortenbach ICM, Thijsen SFT, Dekker AW, Verdonck LF. Increased incidence of EBV-associated lymphoproliferative disorder after bone marrow transplantation due to a change of T cell depletion technique. *Bone Marrow Transplant* 2002; 29: 335-339.
 - 12 **Meijer E**, Dekker AW, Rozenberg-Arska M, Weersink AYL, Verdonck LF. Impact of Cytomegalovirus-seropositivity on mortality in recipients of T-cell depleted bone marrow transplants: contrasting results between recipients of related and unrelated grafts. *Clin Inf Dis* 2002; 35: 703-712.
 - 13 **Meijer E**, Dekker AW, Weersink AYL, Rozenberg-Arska M, Verdonck LF. Prevention and treatment of Epstein-Barr virus associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants: a review. *Br J Haematol* 2002; 119: 596-607.
 - 14 **Meijer E**, Dekker AW, Verdonck LF. Influence of Antithymocyteglobulin dose on outcome in CMV-seropositive recipients of partially T cell depleted stem cell grafts from matched unrelated donors. *Br J Haematol* 2003; 121: 473-476.
 - 15 **Meijer E**, Bloem AC, Dekker AW, Verdonck LF. Effect of Antithymocyteglobulin on quantitative immune recovery and graft-versus-host disease after partially T cell depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. *Transplantation* 2003; 75: 1910-1913.
 - 16 van Kooij B, Thijsen SFT, **Meijer E**, Niesters HGM, van Esser JWJ, Cornelissen JJ, Verdonck LF, van Loon AM. Sequence analysis of EBV DNA isolated from mouth washings and PBMCs of healthy individuals and blood of EBV-LPD patients. *J Clin Virol* 2003; in press.

- 17 **Meijer E**, Boland GJ, Verdonck LF. Prevention of CMV disease in recipients of allogeneic stem cell transplants: a review. *Clinical Microbiology Reviews*; in press.
- 18 **Meijer E**, Cornelissen JJ, Lowenberg B, Verdonck LF. Antithymocyte globulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T cell depleted grafts from matched unrelated donors: a dose finding study. *Experimental Hematology*; in press for publication in November 2003.
- 19 **Meijer E**, Spijkers S, Moschatsis S, Boland GJ, Thijsen SFT, van Loon AM, Verdonck LF. EBV reactivations in recipients of stem cell transplants are frequently caused by re-infections with exogenous EBV strains. Submitted.